Certara, Inc. · NASDAQ:CERT
Certara — Fierce Webinar (October 2022)
33 slides from Certara's conference presentation, Oct 11, 2022
Slide 1: Model-Based Meta-Analysis (MBMA): Optimizing Drug Development with Public Data and Predictive Models
Model-Based Meta-Analysis (MBMA): Optimizing Drug Development with Public Data and Predictive Models www.certara.com
Slide 2: Your Speakers
Your Speakers Jaap Mandema, PhD Matthew Zierhut Chief Innovation Officer Vice President, Integrated Drug Development © Copyright 2022 Certara, L.P. All rights reserved. 2
Slide 3: Questions We Will Answer Today
Questions We Will Answer Today • What is the value proposition for meta-analysis and MBMA? • How is MBMA different from other forms of meta-analysis? • How has MBMA been used to answer real-world drug development questions? © Copyright 2022 Certara, L.P. All rights reserved. 3
Slide 4: Where does meta-analysis and MBMA fit into drug development?
Where does meta-analysis and MBMA fit into drug development? Utilizing all available data can lead to better decisions: • Drug development decisions (R&D) • Commercial/Marketing or other critical decisions DATA SOURCE Clinical Trials Other (or pre-clinical trials) (not from trials) Patient-Level Pro
Slide 5: Meta-Analysis Incorporates Valuable External Information Into Drug Development Decisions
Meta-Analysis Incorporates Valuable External Information Into Drug Development Decisions • Comparative safety and efficacy o There is a need to evaluate new treatment options against other existing or emerging treatment options (indirectly) for go/no-go decisions, dose selection, trial strategy • En
Slide 6: How can meta-analysis and MBMA improve drug development?
How can meta-analysis and MBMA improve drug development? • Rigorously establish safety/efficacy targets needed for differentiation • Understand what is truly needed to compete in market and achieve technical success • Design cost-effective trials that improve probability of early correct development
Slide 7: Key Steps in the Data Curation Process
Key Steps in the Data Curation Process • Formulation of study objectives and protocol • Literature search o Pubmed, clintrials/eudract, company websites/CSRs, conference abstracts/posters/talks • Review and quality assessment of data sources • Selection of data sources for inclusion • Data extractio
Slide 8: Clinical Outcomes Database Explorer (CODEx)
Clinical Outcomes Database Explorer (CODEx) CODEx is a web-based software platform that stores curated clinical outcomes databases and provides an interactive platform to quickly investigate indication- specific databases and perform initial exploratory analytics codex.certara.com/codex © Copyright
Slide 9: Filtering to relevant data enables impactful exploratory analyses
Results from over 400 RA studies are available Filtering to relevant data enables impactful exploratory analyses © Copyright 2022 Certara, L.P. All rights reserved. 9
Slide 10: Significant between-trial heterogeneity in tofacitinib treatment effect
Significant between-trial heterogeneity in tofacitinib treatment effect Asian majority trials may help explain some of this heterogeneity © Copyright 2022 Certara, L.P. All rights reserved. 10
Slide 11: Adalimumab, baricitinib, and tofacitinib are more effective than placebo
Adalimumab, baricitinib, and tofacitinib are more effective than placebo Baricitinib has apparent dose-response © Copyright 2022 Certara, L.P. All rights reserved. 11
Slide 12: Baricitinib dose-response more apparent versus adalimumab
Baricitinib dose-response more apparent versus adalimumab Baricitinib 8mg and tofacitinib 10mg appear more effective than adalimumab © Copyright 2022 Certara, L.P. All rights reserved. 12
Slide 13: Majority Asian trials have an impact on anti-TNF treatment effect
Majority Asian trials have an impact on anti-TNF treatment effect © Copyright 2022 Certara, L.P. All rights reserved. 13
Slide 14: MBMA takes advantage of pharmacological/physiological insights
MBMA takes advantage of pharmacological/physiological insights • Model-based meta-analysis (MBMA) is a type of meta-analysis that incorporates parametric models for the effect of treatment, time, and patient population characteristics on the outcomes o Explicitly incorporates the effect of dose and
Slide 15: MBMA Case study: Phase II to III decision point for baricitinib in RA
MBMA Case study PHASE II to III decision point for baricitinib in RA © Copyright 2022 Certara, L.P. All rights reserved. 15
Slide 16: Typical MBMA application is to compare phase II results against other treatment options
Typical MBMA application is to compare phase II efficacy/safety results for novel treatment options against other treatment options; marketed or in development Phase II results in RA for baricitinib, a JAK inhibitor What is the probability to have a better efficacy/safety profile vs. other treatmen
Slide 17: MBMA of time course of ACR20/50/70 shows consistent dose response
MBMA of time course of ACR20/50/70 shows that ACR dose response relationship is consistent and well characterized for all TNF inhibitor across trials (symbol size~precision) 𝑃𝑃(𝐴𝐴𝐴𝐴𝐴𝐴 )𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 = 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 −1 𝐸𝐸𝑜𝑜𝑖𝑖𝑖𝑖𝑘𝑘 + 𝑓𝑓 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑖𝑖𝑖𝑖…
Slide 18: The decline of baseline CRP over the past 20 years explains the drift in treatment effect
Treatment response for ACR is significantly dependent on baseline CRP The decline of baseline CRP over the past 20 years explains the drift in treatment effect for anti-TNFs •Treatment effect was dependent on: baseline CRP, % of patients on background MTX, and Asian/non-Asian (especially for JAKs).
Slide 19: Comparative efficacy for baricitinib relative to other treatment options in RA
Comparative efficacy for baricitinib relative to other treatment options in RA [95% CI] baseline CRP=2 mg/dl; MTX background; placebo=11% for ACR50 © Copyright 2022 Certara, L.P. All rights reserved. 19 19
Slide 20: Probability of ACR20 trial outcome
Probability of phase III trial outcome for ACR20 comparing baricitinib to 40 mg q2w adalimumab compared to observed outcome of RA-BEAM trial • Baricitinib 4 mg/day vs. observed outcome adalimumab 40 mg q2w • Trial simulation predicts a high, 92%, probability of non-inferiority Probability of ACR20 t
Slide 21: Close agreement between simulated and observed trial outcomes of phase III program
Close agreement between simulated and observed trial outcomes of phase III program confirms that we can evaluate design options based on probability models (all simulations based on phase II data only) observed outcome Predicted outcome Phase III differed from phase II in trial duration; failed prio
Slide 22: Pharmacological assumption of similar maximal effect among JAK inhibitors
Pharmacological assumption of similar maximal effect among JAK inhibitors could have increased confidence in phase III decisions BLUE: estimated dose response at end of phase II based on baricitinib data alone RED: estimated dose response at end of phase II assuming a similar Emax among JAK inhibito
Slide 23: Difference in Therapeutic Index among the JAK inhibitors
Comparison of neutrophils vs. ACR Dose Response shows a difference in Therapeutic Index among the JAK inhibitors Drug ED50 neutrophils ED50 ACR (mg/day) (mg/day) Baricitinib (JAK 1/2) 3.2 [1.5 -6.8] 1.8 [1.3 - 2.6] Tofacitinib (JAK 1/3) 8.4 [5.0 - 14.3] 4.3 [3.1 - 6.1] Filgotinib (JAK 1) 109 [43 - 2
Slide 24: JADN is well predicted based on tofacitinib data
The difference from placebo in ACR response in the Japanese phase II study I4V-JE- JADN is well predicted based on tofacitinib data The predicted effect is 46% [28 to 64%; 95% CI] greater in Japanese studies vs. ROW; this difference was estimated from tofacitinib and applied to baricitinib © Copyrig
Slide 25: Week 4 treatment effect is predictive for later time-points
Week 4 treatment effect is predictive for later time-points From: Wang et al. J Clin Pharmacol. 2015 Oct 30. doi: 10.1002/jcph.668. © Copyright 2022 Certara, L.P. All rights reserved. 25
Slide 26: IL-6 vs. other mechanisms
There is strong correlation between DAS score and ACR response that is different for IL-6 vs. other mechanisms Risk difference sarilumab (orange) vs. adalimumab (blue): IL-6 mechanism ACR20: 13.4 [3.8 - 23] ACR50: 15.9 [6.2 - 26] ACR70: 11.5 [3.8 - 19] DAS LDA: 28.8 [20 - 38] DAS rem: 19.6 [12 - 27]
Slide 27: Synthetic Control Arm for Placebo in RA (DAS score)?
Synthetic Control Arm for Placebo in RA (DAS score)? Dark blue area is CI; light blue area is prediction interval • Observed (red dots) vs. estimated (black line) time course of placebo DAS score change from baseline for RA patients. • Whereas there is a very large amount of prior data for the place
Slide 28: To maximize the utility of MBMA, develop comparator models in advance
To maximize the utility of MBMA, develop and maintain comparator models in advance of key decision points TIME EXPENDITURE IN MBMA (APPROXIMATE) Simulations Model Development Data Exploration Data Extraction Data Augmentation © Copyright 2022 Certara, L.P. All rights reserved. 28
Slide 29: MBMA provides a quantitative framework to leverage external data
MBMA provides a quantitative framework to leverage valuable external data into development and regulatory decisions • Comparative safety and efficacy o There is a need to evaluate new treatment options against other existing or emerging treatment options (indirectly) for go/no-go decisions, dose sel
Slide 30: All questions are welcome!
All questions are welcome! Model-Based Meta-Analysis (MBMA): Optimizing Drug Development with Public Data and Predictive Models codex.certara.com www.certara.com
Slide 31: Reading Materials
Reading Materials • Lalonde et al. Model-based drug development. Clin. Pharmacol. Ther. 82: 21-32 (2007). • Milligan et al. Model-Based Drug Development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther. 93(6): 502-14 (2013). • Visser et al. Implementation of Quant
Slide 32: Adalimumab or certolizumab? ACR20 or ACR50?
What is the optimal endpoint or comparator for phase III? Adalimumab or certolizumab? ACR20 or ACR50? © Copyright 2022 Certara, L.P. All rights reserved. 32
Slide 33: Probability of trial outcome conditional on effect size
Probability of trial outcome conditional on effect size and probability of baricitinib to achieve effect size Probability of Trial Out baracitinib 4 vs. adalimimab (N=400/arm, alpha=0 1.0 outcome superior non inferior (10%) inconclusive 0.8 inferior 0.6 0.4 0.2 0.0 -15 -12.5 -10 -7.5 -5 -2.5 0 2.5 5